STUDY OF OCTREOTIDE IN THE MANAGEMENT OF NEUROENDOCRINE TUMORS
(1997)
Abstract :
Evaluate the antitumor effect of octreotide at maximally tolerated doses against carcinoid and pancreatic islet cell tumors. Determine the specificity of octreotide's inhibitory effect in a dose/response relationship on the endogenous release of neuroendocrine tumor products.
| Project Number : | 5M01RR000095-370379 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | drug screening /evaluation, endocrine neoplasm, gastrointestinal neoplasm, human therapy evaluation, neoplasm /cancer chemotherapy, octreotide, pancreatic islet neoplasm antineoplastic, neuroendocrine system, outcomes research clinical research, human subject |
|---|
PHASE I STUDY OF SOMATULINE IN THE MANAGEMENT OF LUNG CANCER
(1997)
Abstract :
The treatment of small cell lung cancer (SCLC) remains a major challenge confronting cancer physicians. SCLC varies from neuroectodermal origin and synthesizes and secretes a large number of peptide hormones.
| Project Number : | 5M01RR000095-370420 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | antineoplastic, drug screening /evaluation, human therapy evaluation, neoplasm /cancer chemotherapy, small cell lung cancer clinical trial phase I clinical research, human subject |
|---|
VU SANDO LAR 2 A TOLERABILITY & EFFICACY OF MULTIPLE DOSES OF SANDOSTATIN
(1997)
Abstract :
To determine the efficacy of 10 20 and 30 mg dose of Sandostatin-LAR compared to subcutaneous Sandostatin in providing continuous symptomatic control of malignant carcinoid syndrome when given at intervals of four weeks. To test the safety and tolerability of sequential doses of Sandostatin-LAR in carcinoid patients. To investigate the pharmacokinetic/pharmacodynamic profile of Sandostatin-Lar. To assess the dose proportionally of serum octreotide concentrations of Sandostatin-LAR at doses of 10,20, 30 mg when given at intervals of four weeks.
| Project Number : | 5M01RR000095-370522 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | dosage, drug adverse effect, drug screening /evaluation, neoplasm /cancer chemotherapy, octreotide, pharmacokinetics clinical research, human subject |
|---|
COMPARATIVE, 2 WAY CROSSOVER MULTIPLE DOSE OF IV/ORAL REGIMEN OF MESNA
(1997)
Abstract :
To compare the clinical efficacy of mesna given by the approved intravenous regimen of 20% of the ifosfamide dose at 0,4 and 8 hours to the proposed intravenous and oral dosing regimen in which intravenous mesna at 205 of the ifosfamide dose is given at 0 hour and mesna tablets at 40% of the ifosfamide dose are administered at 2 and 6 hours, in the prevention of ifosfasmide-induced hematuria.
| Project Number : | 5M01RR000095-370530 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | MESNA, chemoprevention, dosage, drug administration route, drug screening /evaluation, hematuria, human therapy evaluation, neoplasm /cancer chemotherapy clinical trial, drug adverse effect, intravenous administration, oral administration clinical research, human subject |
|---|
ROUTES OF IFOSFAMIDE METABOLISM
(1997)
Abstract :
Ifosamide (IFOS) and its isomer, cyclophosphamide (CPA), are members of the oxazaphosphorine class of alkylating agents used in cancer chemotherapy. IFOS is a recently approved drug whereas CPA has been used extensively as an antitumor and immunosuppressant agent for the last 30 years. IFOS, like CPA, undergoes microsomal activation. Unlike CPA, IFOS has N-dealkylation metabolites which may comprise a major route of elimination for some patients and may comprise a major route of elimination for some patients and may account for its different toxicity profile. A limitation in further understanding the pharmacology of IFOS and potential drug interactions is a lack of method to measure its tumor active metabolites. The specific aims of this project include: a) developing techniques to quantitate the metabolism of IFOS b) to compare the metabolism of CPA to IFOS and identify factors significantly influencing IFOS' disposition c) to determine whether the uroprotective agent mesna, significantly alters the amount of cytotoxic IFOS formed by oxidative metabolism and (d to characterize IFOS' metabolism in patients. The major limitation in studying oxazaphosphorine pharmacology has been the lack of chromophore in the ring structure. Methods to measure IFOS an its metabolites will involve modifying a TLC and HPLC method used for CPA. We have previously used a thin-layer chromatography (TLC) assay to measure CPA's metabolism in animals and humans. We wish to modify this TLC assay for the detection of IFOS' major metabolic products. 3H-IFOS is to be used. The radiolabel on the chloroethyl side chain attached to the endocyclic nitrogen atom will allow for the measurement of all metabolites except for acrolein and dechloroethyl-cyclophosphamide. A recently described ion pair HPLC method for CPA will be adapted for IFOS and compared to results obtained using the TLC method. After the optimal methods are developed for quantitating IFOS and its metabolic products, human studies will follow. With the development of TLC or HPLC techniques to quantitate IFOS' metabolism, factors which affect CPA's metabolism can be evaluated for IFOS. These factors include the influence of genetic P-450 isoenzyme inheritance patterns and the influence of known inhibitors of various P- 450 isoenzymes. IFOS' metabolism in female Sprague-Dawley rats will be compared with metabolism in female Dark Agouti rats, which lack cytochrome IID6. The metabolism of IFOS by isolated perfused liver preparations will be measured in the presence of agents which inhibit cytochrome P-450 including cimetidine, SKF-525A, metyrapone and ketoconazole. The glutathione scavenging agent, mesna, which is used in combination with IFOS, protects patients from the urotoxic IFOS metabolite, acrolein. Whether mesna alters the amount of IFO antitumor metabolites formed will be another factor evaluated by these models. In vitro microsomal IFOS activation will be used to further identify mechanisms of inhibition. When IFOS' metabolic routes have been quantitated using the HPLC and TLC methodology in animal models, IFOS pharmacokinetics can then be extended to newly diagnosed cancer patients. Using these techniques, the potential interaction between IFOS and mesna can be studied in humans.
| Project Number : | 5R29CA057464-03 |
|---|
| ICD : | NATIONAL CANCER INSTITUTE |
|---|
| IRG : | ET |
|---|
| Project Terms : | antineoplastic, cyclophosphamide, drug interaction, drug metabolism, ifosfamide, neoplasm /cancer pharmacology, technology /technique alkylating agent, cytochrome P450, cytotoxicity, isomer, isozyme, model, oxidative phosphorylation genetic strain, high performance liquid chromatography, human subject, isolation perfusion, laboratory rat, thin layer chromatography |
|---|
ROUTES OF IFOSFAMIDE METABOLISM
(1997)
Abstract :
Ifosamide (IFOS) and its isomer, cyclophosphamide (CPA), are members of the oxazaphosphorine class of alkylating agents used in cancer chemotherapy. IFOS is a recently approved drug whereas CPA has been used extensively as an antitumor and immunosuppressant agent for the last 30 years. IFOS, like CPA, undergoes microsomal activation. Unlike CPA, IFOS has N-dealkylation metabolites which may comprise a major route of elimination for some patients and may comprise a major route of elimination for some patients and may account for its different toxicity profile. A limitation in further understanding the pharmacology of IFOS and potential drug interactions is a lack of method to measure its tumor active metabolites. The specific aims of this project include: a) developing techniques to quantitate the metabolism of IFOS b) to compare the metabolism of CPA to IFOS and identify factors significantly influencing IFOS' disposition c) to determine whether the uroprotective agent mesna, significantly alters the amount of cytotoxic IFOS formed by oxidative metabolism and (d to characterize IFOS' metabolism in patients. The major limitation in studying oxazaphosphorine pharmacology has been the lack of chromophore in the ring structure. Methods to measure IFOS an its metabolites will involve modifying a TLC and HPLC method used for CPA. We have previously used a thin-layer chromatography (TLC) assay to measure CPA's metabolism in animals and humans. We wish to modify this TLC assay for the detection of IFOS' major metabolic products. 3H-IFOS is to be used. The radiolabel on the chloroethyl side chain attached to the endocyclic nitrogen atom will allow for the measurement of all metabolites except for acrolein and dechloroethyl-cyclophosphamide. A recently described ion pair HPLC method for CPA will be adapted for IFOS and compared to results obtained using the TLC method. After the optimal methods are developed for quantitating IFOS and its metabolic products, human studies will follow. With the development of TLC or HPLC techniques to quantitate IFOS' metabolism, factors which affect CPA's metabolism can be evaluated for IFOS. These factors include the influence of genetic P-450 isoenzyme inheritance patterns and the influence of known inhibitors of various P- 450 isoenzymes. IFOS' metabolism in female Sprague-Dawley rats will be compared with metabolism in female Dark Agouti rats, which lack cytochrome IID6. The metabolism of IFOS by isolated perfused liver preparations will be measured in the presence of agents which inhibit cytochrome P-450 including cimetidine, SKF-525A, metyrapone and ketoconazole. The glutathione scavenging agent, mesna, which is used in combination with IFOS, protects patients from the urotoxic IFOS metabolite, acrolein. Whether mesna alters the amount of IFO antitumor metabolites formed will be another factor evaluated by these models. In vitro microsomal IFOS activation will be used to further identify mechanisms of inhibition. When IFOS' metabolic routes have been quantitated using the HPLC and TLC methodology in animal models, IFOS pharmacokinetics can then be extended to newly diagnosed cancer patients. Using these techniques, the potential interaction between IFOS and mesna can be studied in humans.
| Project Number : | 1R29CA057464-01 |
|---|
| ICD : | NATIONAL CANCER INSTITUTE |
|---|
| IRG : | ET |
|---|
| Project Terms : | antineoplastic, cyclophosphamide, drug interaction, drug metabolism, ifosfamide, neoplasm /cancer pharmacology, technology /technique alkylating agent, cytochrome P450, cytotoxicity, isomer, isozyme, model, oxidative phosphorylation genetic strain, high performance liquid chromatography, human clinical subject, isolation perfusion, laboratory rat, thin layer chromatography |
|---|
ROUTES OF IFOSFAMIDE METABOLISM
(1997)
Abstract :
Ifosamide (IFOS) and its isomer, cyclophosphamide (CPA), are members of the oxazaphosphorine class of alkylating agents used in cancer chemotherapy. IFOS is a recently approved drug whereas CPA has been used extensively as an antitumor and immunosuppressant agent for the last 30 years. IFOS, like CPA, undergoes microsomal activation. Unlike CPA, IFOS has N-dealkylation metabolites which may comprise a major route of elimination for some patients and may comprise a major route of elimination for some patients and may account for its different toxicity profile. A limitation in further understanding the pharmacology of IFOS and potential drug interactions is a lack of method to measure its tumor active metabolites. The specific aims of this project include: a) developing techniques to quantitate the metabolism of IFOS b) to compare the metabolism of CPA to IFOS and identify factors significantly influencing IFOS' disposition c) to determine whether the uroprotective agent mesna, significantly alters the amount of cytotoxic IFOS formed by oxidative metabolism and (d to characterize IFOS' metabolism in patients. The major limitation in studying oxazaphosphorine pharmacology has been the lack of chromophore in the ring structure. Methods to measure IFOS an its metabolites will involve modifying a TLC and HPLC method used for CPA. We have previously used a thin-layer chromatography (TLC) assay to measure CPA's metabolism in animals and humans. We wish to modify this TLC assay for the detection of IFOS' major metabolic products. 3H-IFOS is to be used. The radiolabel on the chloroethyl side chain attached to the endocyclic nitrogen atom will allow for the measurement of all metabolites except for acrolein and dechloroethyl-cyclophosphamide. A recently described ion pair HPLC method for CPA will be adapted for IFOS and compared to results obtained using the TLC method. After the optimal methods are developed for quantitating IFOS and its metabolic products, human studies will follow. With the development of TLC or HPLC techniques to quantitate IFOS' metabolism, factors which affect CPA's metabolism can be evaluated for IFOS. These factors include the influence of genetic P-450 isoenzyme inheritance patterns and the influence of known inhibitors of various P- 450 isoenzymes. IFOS' metabolism in female Sprague-Dawley rats will be compared with metabolism in female Dark Agouti rats, which lack cytochrome IID6. The metabolism of IFOS by isolated perfused liver preparations will be measured in the presence of agents which inhibit cytochrome P-450 including cimetidine, SKF-525A, metyrapone and ketoconazole. The glutathione scavenging agent, mesna, which is used in combination with IFOS, protects patients from the urotoxic IFOS metabolite, acrolein. Whether mesna alters the amount of IFO antitumor metabolites formed will be another factor evaluated by these models. In vitro microsomal IFOS activation will be used to further identify mechanisms of inhibition. When IFOS' metabolic routes have been quantitated using the HPLC and TLC methodology in animal models, IFOS pharmacokinetics can then be extended to newly diagnosed cancer patients. Using these techniques, the potential interaction between IFOS and mesna can be studied in humans.
| Project Number : | 5R29CA057464-02 |
|---|
| ICD : | NATIONAL CANCER INSTITUTE |
|---|
| IRG : | ET |
|---|
| Project Terms : | antineoplastic, cyclophosphamide, drug interaction, drug metabolism, ifosfamide, neoplasm /cancer pharmacology, technology /technique alkylating agent, cytochrome P450, cytotoxicity, isomer, isozyme, model, oxidative phosphorylation genetic strain, high performance liquid chromatography, human subject, isolation perfusion, laboratory rat, thin layer chromatography |
|---|
ROUTES OF IFOSFAMIDE METABOLISM
(1996)
Abstract :
Ifosamide (IFOS) and its isomer, cyclophosphamide (CPA), are members of the oxazaphosphorine class of alkylating agents used in cancer chemotherapy. IFOS is a recently approved drug whereas CPA has been used extensively as an antitumor and immunosuppressant agent for the last 30 years. IFOS, like CPA, undergoes microsomal activation. Unlike CPA, IFOS has N-dealkylation metabolites which may comprise a major route of elimination for some patients and may comprise a major route of elimination for some patients and may account for its different toxicity profile. A limitation in further understanding the pharmacology of IFOS and potential drug interactions is a lack of method to measure its tumor active metabolites. The specific aims of this project include: a) developing techniques to quantitate the metabolism of IFOS b) to compare the metabolism of CPA to IFOS and identify factors significantly influencing IFOS' disposition c) to determine whether the uroprotective agent mesna, significantly alters the amount of cytotoxic IFOS formed by oxidative metabolism and (d to characterize IFOS' metabolism in patients. The major limitation in studying oxazaphosphorine pharmacology has been the lack of chromophore in the ring structure. Methods to measure IFOS an its metabolites will involve modifying a TLC and HPLC method used for CPA. We have previously used a thin-layer chromatography (TLC) assay to measure CPA's metabolism in animals and humans. We wish to modify this TLC assay for the detection of IFOS' major metabolic products. 3H-IFOS is to be used. The radiolabel on the chloroethyl side chain attached to the endocyclic nitrogen atom will allow for the measurement of all metabolites except for acrolein and dechloroethyl-cyclophosphamide. A recently described ion pair HPLC method for CPA will be adapted for IFOS and compared to results obtained using the TLC method. After the optimal methods are developed for quantitating IFOS and its metabolic products, human studies will follow. With the development of TLC or HPLC techniques to quantitate IFOS' metabolism, factors which affect CPA's metabolism can be evaluated for IFOS. These factors include the influence of genetic P-450 isoenzyme inheritance patterns and the influence of known inhibitors of various P- 450 isoenzymes. IFOS' metabolism in female Sprague-Dawley rats will be compared with metabolism in female Dark Agouti rats, which lack cytochrome IID6. The metabolism of IFOS by isolated perfused liver preparations will be measured in the presence of agents which inhibit cytochrome P-450 including cimetidine, SKF-525A, metyrapone and ketoconazole. The glutathione scavenging agent, mesna, which is used in combination with IFOS, protects patients from the urotoxic IFOS metabolite, acrolein. Whether mesna alters the amount of IFO antitumor metabolites formed will be another factor evaluated by these models. In vitro microsomal IFOS activation will be used to further identify mechanisms of inhibition. When IFOS' metabolic routes have been quantitated using the HPLC and TLC methodology in animal models, IFOS pharmacokinetics can then be extended to newly diagnosed cancer patients. Using these techniques, the potential interaction between IFOS and mesna can be studied in humans.
| Project Number : | 5R29CA057464-04 |
|---|
| ICD : | NATIONAL CANCER INSTITUTE |
|---|
| IRG : | ET |
|---|
STUDY OF OCTREOTIDE IN THE MANAGEMENT OF NEUROENDOCRINE TUMORS
(1995)
Abstract :
Evaluate the antitumor effect of octreotide at maximally tolerated doses against carcinoid and pancreatic islet cell tumors. Determine the specificity of octreotide's inhibitory effect in a dose/response relationship on the endogenous release of neuroendocrine tumor products.
| Project Number : | 5M01RR000095-350379 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | drug screening /evaluation, endocrine neoplasm, human therapy evaluation, neoplasm /cancer chemotherapy, pancreatic islet neoplasm, peptide hormone analog, somatostatin antineoplastic, dosage, endocrine pharmacology, neoplasm /cancer pharmacology, neuroendocrine system, pharmacokinetics human subject |
|---|
PHASE I STUDY OF SOMATULINE IN THE MANAGEMENT OF LUNG CANCER
(1995)
Abstract :
The treatment of small cell lung cancer (SCLC) remains a major challenge confronting cancer physicians. SCLC varies from neuroectodermal origin and synthesizes and secretes a large number of peptide hormones.
| Project Number : | 5M01RR000095-350420 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | antineoplastic, hormone therapy, human therapy evaluation, neoplasm /cancer chemotherapy, peptide hormone analog, small cell lung cancer, somatostatin clinical trial human subject |
|---|
PHASE I DOSING STUDY OF SANDOSTATIN LAR GIVEN IM IN ADVANCED CANCER
(1995)
Abstract :
Evaluate the safety, tolerability and pharmacokinetics following escalating dosing schedules of Sandostatin LAR in patients with advanced cancer.
| Project Number : | 5M01RR000095-350487 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | drug administration rate /duration, drug screening /evaluation, human therapy evaluation, metastasis, neoplasm /cancer chemotherapy, somatostatin clinical trial, neoplasm /cancer pharmacology, pharmacokinetics human subject |
|---|
STUDY OF OCTREOTIDE IN THE MANAGEMENT OF NEUROENDOCRINE TUMORS
(1994)
Abstract :
Evaluate the antitumor effect of octreotide at maximally tolerated doses against carcinoid and pancreatic islet cell tumors. Determine the specificity of octreotide's inhibitory effect in a dose/response relationship on the endogenous release of neuroendocrine tumor products.
| Project Number : | 5M01RR000095-340379 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | antineoplastic, drug screening /evaluation, gastrointestinal neoplasm, human therapy evaluation, neoplasm /cancer chemotherapy, neuroendocrine system, pancreatic islet neoplasm, somatostatin dosage, endocrine pharmacology, neoplasm /cancer pharmacology, pharmacokinetics human subject |
|---|
PHASE I STUDY OF SOMATULINE IN THE MANAGEMENT OF LUNG CANCER
(1994)
Abstract :
The treatment of small cell lung cancer (SCLC) remains a major challenge confronting cancer physicians. SCLC varies from neuroectodermal origin and synthesizes and secretes a large number of peptide hormones.
| Project Number : | 5M01RR000095-340420 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | antineoplastic, hormone therapy, human therapy evaluation, neoplasm /cancer chemotherapy, peptide hormone analog, small cell carcinoma of lung, somatostatin clinical trial human subject |
|---|
STUDY OF OCTREOTIDE IN THE MANAGEMENT OF NEUROENDOCRINE TUMORS
(1993)
Abstract :
Evaluate the antitumor effect of octreotide at maximally tolerated doses against carcinoid and pancreatic islet cell tumors. Determine the specificity of octreotide's inhibitory effect in a dose/response relationship on the endogenous release of neuroendocrine tumor products.
| Project Number : | 2M01RR000095-330379 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | antineoplastic, drug screening /evaluation, gastrointestinal neoplasm, human therapy evaluation, neoplasm /cancer chemotherapy, neuroendocrine system, pancreatic islet neoplasm, somatostatin dosage, endocrine pharmacology, neoplasm /cancer pharmacology, pharmacokinetics human subject |
|---|
MULTIPLE DOSE URINARY AND SERUM PHARMACOKINETICS OF MESNA AND DIMESNA
(1993)
Abstract :
Assess the pharmacokinetic equivalence of two dosing regimens of Mesna administered to patients receiving ifosfamide for metastatic non-small cell lung cancer.
| Project Number : | 2M01RR000095-330394 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | drug interaction, drug screening /evaluation, ifosfamide, lung neoplasm, neoplasm /cancer chemotherapy, neoplasm /cancer pharmacology, pharmacokinetics, sulfonate detoxification, dosage blood chemistry, human subject, urinalysis |
|---|
ROUTES OF IFOSFAMIDE METABOLISM
(1993)
Abstract :
To develop a method for measuring IFOS and its metabolites in a model system. To compare the metabolism of IFOS with CPA. To determine whether factors affecting CPA metabolism also alter IFOS metabolism.
| Project Number : | 2M01RR000095-330413 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | chemical model, drug metabolism, ifosfamide, measurement, method development, model design /development cyclophosphamide human subject |
|---|
PHASE I STUDY OF SOMATULINE IN THE MANAGEMENT OF LUNG CANCER
(1993)
Abstract :
The treatment of small cell lung cancer (SCLC) remains a major challenge confronting cancer physicians. SCLC aries from neuroectodermal origin and synthesizes and secretes a large number of peptide hormones.
| Project Number : | 2M01RR000095-330420 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | antineoplastic, hormone therapy, human therapy evaluation, neoplasm /cancer chemotherapy, peptide hormone analog, small cell carcinoma of lung, somatostatin clinical study /trial human subject |
|---|
STUDY OF OCTREOTIDE IN THE MANAGEMENT OF NEUROENDOCRINE TUMORS
(1992)
Abstract :
Evaluate the antitumor effect of octreotide at maximally tolerated doses against carcinoid and pancreatic islet cell tumors. Determine the specificity of octreotide's inhibitory effect in a dose/response relationship on the endogenous release of neuroendocrine tumor products.
| Project Number : | 5M01RR000095-320379 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | antineoplastic, gastrointestinal neoplasm, human therapy evaluation, neoplasm /cancer chemotherapy, neuroendocrine system, pancreatic islet neoplasm, peptide hormone analog, somatostatin dosage, pharmacodynamics human clinical subject |
|---|
MULTIPLE DOSE URINARY AND SERUM PHARMACOKINETICS OF MESNA AND DIMESNA
(1992)
Abstract :
Assess the pharmacokinetic equivalence of two dosing regimens of Mesna administered to patients receiving ifosfamide for metastatic non-small cell lung cancer.
| Project Number : | 5M01RR000095-320394 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | dosage, drug drug interaction, ifosfamide, lung neoplasm, neoplasm /cancer chemotherapy, pharmacodynamics, sulfonate detoxication, drug adverse effect blood chemistry, human clinical subject, urinalysis |
|---|
PHASE I STUDY OF OCTREOTIDE IN THE MANAGEMENT OF NEUROENDOCRINE TUMORS
(1991)
Abstract :
SMS 201-995 is a synthetic congener of somatostatin that qualitatively resembles those of the natural peptide. In patients with carcinoid syndrome, it has been shown to reduce the frequency of flushing attacks as well as to improve a sense of general well-being. There is a reduction in the production of serotonin as reflected by a decrease in the urinary excretion of 5-hydroxyindole observations followed by sequential evaluations while on the drug.
| Project Number : | 5M01RR000095-310379 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | endocrine neoplasm, human therapy evaluation, neoplasm /cancer hormone therapy, nervous system neoplasm, synthetic peptide clinical study /trial human clinical subject |
|---|
PHARMACOGENETIC ASPECTS OF CYCLOPHOSPHAMIDE METABOLISM
(1990)
Abstract :
Cyclophosphamide is a widely used antineoplastic which undergoes microsomal metabolism for activation. Recent evidence indicates that the ability to metabolize certain drugs depends on genetic inheritance. Studies of cyclophosphamide metabolism in man are planned to investigate the potential for genetic control of this drugs metabolism.
| Project Number : | 5M01RR000095-300289 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | ANTINEOPLASTIC AGENTS, DRUGS, PHARMACOLOGY, BIOCHEMICAL, GENETICS, PHARMACOGENETICS, HALOALKYLAMINES, CYCLOPHOSPHAMIDE, NEOPLASMS PHARMACOLOGY METABOLISM, BIOTRANSFORMATION, OXIDATION-REDUCTION, OXIDATION HUMAN, CLINICAL |
|---|
PHARMACOGENETIC ASPECTS OF CYCLOPHOSPHAMIDE METABOLISM
(1989)
| Project Number : | 5M01RR000095-290289 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | ANTINEOPLASTIC AGENTS, DRUGS, PHARMACOLOGY, BIOCHEMICAL, GENETICS, PHARMACOGENETICS, HALOALKYLAMINES, CYCLOPHOSPHAMIDE, NEOPLASMS PHARMACOLOGY OXIDATION-REDUCTION, OXIDATION HUMAN, CLINICAL |
|---|
PHARMACOLOGIC ASPECTS OF CYCLOPHOSPHAMIDE METABOLISM
(1989)
| Project Number : | 2S07RR005424-280352 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
PHARMACOLOGIC ASPECTS OF CYCLOPHOSPHAMIDE METABOLISM
(1989)
| Project Number : | 2S07RR005424-280979 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
PHARMACOGENETIC ASPECTS OF CYCLOPHOSPHAMIDE METABOLISM
(1988)
| Project Number : | 2M01RR000095-280289 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|
| Project Terms : | ANTINEOPLASTIC AGENTS, DRUGS, PHARMACOLOGY, BIOAVAILABILITY, GENETICS, PHARMACOGENETICS, HALOALKYLAMINES, CYCLOPHOSPHAMIDE, NEOPLASMS PHARMACOLOGY HUMAN, CLINICAL |
|---|
PHARMACOLOGIC ASPECTS OF CYCLOPHOSPHAMIDE METABOLISM
(1988)
| Project Number : | 2S07RR005424-270430 |
|---|
| ICD : | NATIONAL CENTER FOR RESEARCH RESOURCES |
|---|